MinuteClinic opens 14 clinics in Los Angeles area
IRVINE, Calif MinuteClinic, a subsidiary of CVS Caremark, has announced the opening of 14 in-store health clinics in the Los Angeles metro area. By year’s end, the company expects to open up 11 more clinics in the metro area.
In Orange County, MinuteClinic has developed a community educational partnership with St. Joseph Health System, a highly regarded healthcare provider that has fulfilled its mission of improving the health and quality of life of the communities it serves for over 75 years. In addition to Mission Hospital in Mission Viejo, St. Jude Medical Center in Fullerton and St. Joseph Hospital in Orange, St. Joseph Health System provides a host of services including outpatient surgery, rehabilitation services, community clinics, home health and hospice care. St Joseph Health System will collaborate with MinuteClinic on patient and community health care education programs.
MinuteClinic is in-network with the following insurers for patients in the Los Angeles area: Aetna, Assurant Health, Beech Street, CBSA, Choice Care Network (PPO)-Humana affiliate, CIGNA, Humana, Medicare, PBA (Preferred Benefit Administrators), ppoNext (Los Angeles County only), United Healthcare (effective 10/15 in Los Angeles County and 11/1 in Orange and San Bernardino counties).
Mylan announces new appointments
PITTSBURGH Upon the news of the acquisition involving Merck’s KGaA generic business by Mylan, Mylan released a group of statements regarding new appointments to positions within the company worldwide.
The appointments include: Harry Korman as President, North America; Rajiv Malik as Executive Vice President in charge or Global Technical Operations; Carolyn Myers, Ph.D. President-elect of Dey; Christy Taylor as Chief Operating Officer of Dey; Didier Barret as President of Europe, Middle East, and Africa; Heather Bresch as Chief Operating Officer; and John Montgomery as President, Asia Pacific.
Mylan acquired Merck’s generics for $6.8 billion in cash.
FDA approves Afluria flu vaccine
AUSTRALIA The Food and Drug Administration has approved CSL’s flu vaccine Afluria, according to The Australian.
The company expects to ship two million doses as part of its first shipment to the U.S. between mid-December and early February. The company expects to increase its export to 20 million doses over the next four years.
“We’ve entered the US market quite late, but over the next few years we hope to increase our export of flu vaccine to the US to 20 million doses,” CSL’s Dr Rachel David said.